1,336 research outputs found
Spectroscopic Monitoring Observations of Nova V1724 Aql in 2012
Spectroscopic and photometric monitoring observations of nova Apl 2012 (V1724 Apl) were conducted at Koyama Astronomical Observatory, Fujii-Kurosaki Observatory and Bisei Astronomical Observatory. The nova was initially considered as an outbursting pre-main-sequence young stellar object. Our monitoring observations have revealed the nova to be a Fe II type classical nova. The temporal evolution of spectra and light curves of the nova were similar to those of a slow nova (e.g., V1280 Sco and V5558 Sgr). We observed no evidence of molecule formation in V1724 Aql in contrast with V2676 Oph in which dust formation occurred after the molecular formation in the nova outflow
Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice
The purpose of the study is to evaluate the tumour enhancing characteristics and biodistribution of a newly developed metalloporphyrin derivative, HOP-9P (13, 17-bis (1-carboxypropionyl) carbamoylethyl-3, 8-bis (1-phenylpropyloxyethyl)-2,7,12,18-tetra- methyl-porphynato manganese (III)). Seven mice bearing SCC VII tumours were imaged using T1-weighted conventional spin echo magnetic resonance images before and 5 min, 2 h and 24 h after intravenous injection of 0.1 mmol/kg of HOP-9P. For the acquired images, signal intensities of the tumour, muscle and oil-phantom were measured. Then, tumor/oil and tumor/muscle signal intensity ratios were calculated. Nineteen mice were sacrificed before or after the administration of HOP-9P (at 5 min, 2 h and 24 h), and the biodistribution of manganese in the tumour, muscle, liver, blood and kidneys was measured using optical emission spectrometers and was expressed as micrograms of manganese per gram of tissue. The tumour/muscle signal intensity ratio at 24 h (3.18 ± 0.34) was significantly higher than precontrast ratio (1.77 ± 0.20) (P < 0.05). The biodistribution assessment of manganese demonstrated that HOP-9P gradually and consistently accumulated in the tumour to reach the highest concentration at 24 h (3.49 ± 1.22 μ gMn/g). It is concluded that HOP-9P is a potential tumour-specific MR contrast agent. © 2001 Cancer Research Campaign http://www.bjcancer.co
Senescence marker protein 30 in acute liver failure: validation of a mass spectrometry proteomics assay
<p>Abstract</p> <p>Background</p> <p>Our previous proteomic study showed that the senescence marker protein (SMP30) is selectively present in the plasma of a murine model of acute liver failure (ALF). The aim of this study was to validate this SMP30 expression in the plasma and liver tissues of mice and humans with ALF.</p> <p>Methods</p> <p>After the proteomic analysis of plasma from a murine model of D-galactosamine/lipopolysaccharide (GalN/LPS)-induced ALF by two-dimensional electrophoresis (2-DE) and mass spectrometry, the expression levels of SMP30 in the plasma and liver tissues were validated by western blot and RT-PCR analyses. These results were then confirmed in plasma samples from humans.</p> <p>Results</p> <p>These data validate the results of 2-DE, and western blot showed that SMP30 protein levels were only elevated in the plasma of ALF mice. Further analysis revealed that GalN/LPS induced the downregulation of SMP30 protein levels in liver tissues (by approximately 25% and 16% in the GalN/LPS-treated mice and in the treated mice that survived, respectively; <it>P </it>< 0.01). Hepatic SMP30 mRNA levels decreased by about 90% only in the mice that survived the GalN/LPS treatment. Importantly, plasma obtained from patients with ALF also contained higher levels of SMP30, about (3.65 ± 0.34) times those observed in healthy volunteers.</p> <p>Conclusion</p> <p>This study shows that SMP30 is not only a potential biomarker for the diagnosis and even prognosis of ALF. It also plays a very important role in a self-protective mechanism in survival and participates in the pathophysiological processes of ALF.</p
HGPD: Human Gene and Protein Database, 2012 update
The Human Gene and Protein Database (HGPD; http://www.HGPD.jp/) is a unique database that stores information on a set of human Gateway entry clones in addition to protein expression and protein synthesis data. The HGPD was launched in November 2008, and 33 275 human Gateway entry clones have been constructed from the open reading frames (ORFs) of full-length cDNA, thus representing the largest collection in the world. Recently, research objectives have focused on the development of new medicines and the establishment of novel diagnostic methods and medical treatments. And, studies using proteins and protein information, which are closely related to gene function, have been undertaken. For this update, we constructed an additional 9974 human Gateway entry clones, giving a total of 43 249. This set of human Gateway entry clones was named the Human Proteome Expression Resource, known as the ‘HuPEX’. In addition, we also classified the clones into 10 groups according to protein function. Moreover, in vivo cellular localization data of proteins for 32 651 human Gateway entry clones were included for retrieval from the HGPD. In ‘Information Overview’, which presents the search results, the ORF region of each cDNA is now displayed allowing the Gateway entry clones to be searched more easily
Methods for Reducing False Alarms in Searches for Compact Binary Coalescences in LIGO Data
The LIGO detectors are sensitive to a variety of noise transients of
non-astrophysical origin. Instrumental glitches and environmental disturbances
increase the false alarm rate in the searches for gravitational waves. Using
times already identified when the interferometers produced data of questionable
quality, or when the channels that monitor the interferometer indicated
non-stationarity, we have developed techniques to safely and effectively veto
false triggers from the compact binary coalescences (CBCs) search pipeline
Low- and Medium-Dispersion Spectropolarimetry of Nova V475 Sct (Nova Scuti 2003): Discovery of an Asymmetric High-Velocity Wind in a Moderately Fast Nova
We present low-resolution () and medium-resolution ()
spectropolarimetry of Nova V475 Sct with the HBS instrument, mounted on the
0.91-m telescope at the Okayama Astrophysical Observatory, and with FOCAS,
mounted on the 8.2-m Subaru telescope. We estimated the interstellar
polarization toward the nova from the steady continuum polarization components
and H line emission components. After subtracting the interstellar
polarization component from the observations, we found that the H
emission seen on 2003 October 7 was clearly polarized. In the polarized flux
spectrum, the H emission had a distinct red wing extending to km s and a shoulder around km s, showing a
constant position angle of linear polarization \theta_{\rm *}\simeq
155\arcdeg\pm 15\arcdeg. This suggests that the nova had an asymmetric outflow
with a velocity of km s or more, which is six
times higher than the expansion velocity of the ionized shell at the same
epoch. Such a high-velocity component has not previously been reported for a
nova in the `moderately fast' speed class. Our observations suggest the
occurrence of violent mass-loss activity in the nova binary system even during
the common-envelope phase. The position angle of the polarization in the
H wing is in good agreement with that of the continuum polarization
found on 2003 September 26 (--0.6 %), which disappeared
within the following 2 d. The uniformity of the PA between the continuum
polarization and the wing polarization on October 7 suggests that the axis of
the circumstellar asymmetry remained nearly constant during the period of our
observations.Comment: 27 pages, 7 figures, accepted for publication in A
- …